42945-65-3

Basic information

• Product Name: Ethyl 2-MethoxyethaniMidoate hydrochloride
• Synonyms: Ethyl 2-MethoxyethaniMidoate hydrochloride
• CAS NO: 42945-65-3
• Molecular Formula: C₅H₁₁NO₂*ClH
• Molecular Weight: 153.60728
• Mol File: 42945-65-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 2-MethoxyethaniMidoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-MethoxyethaniMidoate hydrochloride(42945-65-3)
• EPA Substance Registry System: Ethyl 2-MethoxyethaniMidoate hydrochloride(42945-65-3)

Safety Data

• Hazardous Substances Data: 42945-65-3(Hazardous Substances Data)

Upstream product

• 1738-36-9 2-methoxyacetonitrile 
• 64-17-5 ethanol 

Downstream Products

• 1903-91-9 2-methoxyethanimidamide hydrochloride 
• 3122-73-4 2-methoxyacetamidine 
• 84353-10-6 2-Methoxy-5-methoxymethyl-1,3,4-thiadiazol 
• 54623-59-5 ((4S)-2-methoxymethyl-5t-phenyl-4,5-dihydro-oxazol-4r-yl)-methanol 
• 16332-06-2 methoxyacetamide 
• 3938-96-3 ethyl 2-methoxyacetate 
• 58995-66-7 triethyl 2-methoxyorthoacetate 

Relevant articles and documents

1,2,4-TRIAZOL-5-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-lR), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

Mapping pilicide anti-virulence effect in Escherichia coli, a comprehensive structure-activity study

Pilicides prevent pili formation and thereby the development of bacterial biofilms in Escherichia coli. We have performed a comprehensive structure activity relationship (SAR) study of the dihydrothiazolo ring-fused 2-pyridone pilicide central fragment by varying all open positions. Orthogonal projections to latent structures discriminant analysis (OPLS-DA) was used to distinguish active from inactive compounds in which polarity proved to be the most important factor for discrimination. A quantitative SAR (QSAR) partial least squares (PLS) model was calculated on the active compounds for prediction of biofilm inhibition activity. In this model, compounds with high inhibitory activity were generally larger, more lipophilic, more flexible and had a lower HOMO. Overall, this resulted in both highly valuable SAR information and potent inhibitors of type 1 pili dependent biofilm formation. The most potent biofilm inhibitor had an EC50 of 400 nM.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).